According to the information on April 3 on the website of the State Food and Drug Administration (CFDA), the application for the production of 3.1 antifungal drug kapofen acetate was accepted
According to the public information, kapofungin acetate is suitable for the treatment of invasive aspergillosis that is ineffective or intolerable to other treatments, as well as for the suspected fungal infection of people with neutropenia and fever
The original research drug is "Kosis" developed by MSD, which entered the Chinese market in 2009
CFDA shows that at present, only the original research drug is on sale in China, and there is no domestic enterprise producing kapofungin acetate API and related preparations
In addition to Huadong pharmaceutical, Hengrui Pharmaceutical (600276
SH) has applied for the production approval documents of carbaryl acetate API and injection, and aosaikang has applied for the production approval documents of API
East China medicine is the leading double ingredient in the field of immunity and hypoglycemic drugs in China
The field of anti severe infection, anti-tumor and cardiovascular is the new field that the company will focus on in the next three years.